Biocytogen and Hansoh Pharma announce an antibody license agreement

Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules

CNS Pharmaceuticals appoints Faith L. Charles as Chair of the Board of Directors

Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations

Hester to develop low pathogenic avian influenza inactivated vaccine for poultry

The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals

Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies

Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze

GeneQuantum and WuXi XDC enter into strategic cooperation to empower innovative bioconjugates development

Advent International to acquire a significant stake in Suven Pharmaceuticals

Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US

Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)

Stelis receives recommendation from EMA granting market authorization for Kauliv

Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.